3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
109
pembrolizumab
93
Pemetrexed
83
Cisplatin
67
Specimen Handling
41
durvalumab
36
Paclitaxel
36
Nivolumab
33
Docetaxel
33
atezolizumab
30
Magnetic Resonance Spectroscopy
30
osimertinib
29
Radiotherapy
21
Gemcitabine
21
Etoposide
21
130-nm albumin-bound paclitaxel
19
Cetuximab
17
amivantamab
14
Radiosurgery
13
Radiation
12
Platinum
12
Bevacizumab
12
lazertinib
11
cemiplimab
11
Taxes
11
Immunoglobulin G
11
Topotecan
10
Ipilimumab
10
Drug Therapy
10
Disulfides
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Thoracic
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled